From: aacr.org Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with newly diagnosed human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has either metastasized or cannot be removed with surgery. Concurrently, two tests …
Triple negative breast cancer cells use new strategy to boost metastatic ability
Source: Baylor College of Medicine From: news-medical.net Researchers at Baylor College of Medicine have uncovered a strategy that triple negative breast cancer (TNBC) cells use to boost their ability to metastasize, or spread to other organs. Metastasis is the leading cause of cancer-related deaths and scientists are investigating ways to prevent it. These findings, published in Nature Communications, highlight new …
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
By: Sabrina Serani From: targetedonc.com Key Takeaways Multiomic profiling, including whole exome and transcriptome sequencing, offers prognostic value beyond standard HER2 immunohistochemistry. HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. Elevated ABCC1 expression is associated with poorer outcomes, indicating its role in resistance to T-DXd. Integrating multiomic data into clinical practice …
Tucatinib Enhances First-Line Maintenance Outcomes in HER2-Positive Metastatic Breast Cancer
By: Alexandra Gerlach, Editor From: pharmacytimes.com Key Takeaways Tucatinib added to trastuzumab and pertuzumab improved PFS by 8.6 months in patients with HER2+ metastatic breast cancer. The HER2CLIMB-05 trial showed consistent PFS benefits across subgroups, including those with brain metastases. Common adverse events with tucatinib included diarrhea and elevated liver enzymes, with manageable severity. Tucatinib integration into first-line maintenance therapy …
Evolving Strategies in the Management of HR+, HER2– Metastatic Breast Cancer
By: Guilherme Nader-Marta, MD, Erica L. Mayer, MD, MPH From: onclive.com Key Takeaways Sacituzumab govitecan improved PFS in untreated advanced TNBC patients not eligible for PD-(L)1 inhibitors, as shown in the ASCENT-03 trial. The ASCENT-04 trial demonstrated enhanced PFS with sacituzumab govitecan plus pembrolizumab in PD-L1–positive TNBC compared to chemotherapy plus pembrolizumab. Safety analysis indicated a favorable benefit/risk profile for …
FDA OKs Study Progression of (Z)-Endoxifen in Metastatic Breast Cancer
By: Roman Fabbricatore From: cancernetwork.com The FDA issued a “Study May Proceed” letter for a new study investigating oral (Z)-endoxifen in patients with metastatic breast cancer, according to a news release from the developer, Atossa Therapeutics.1 The subject of a recent investigational new drug (IND) application, the ongoing study aims to provide a new therapeutic strategy for patients with estrogen …
Where you live may be fueling aggressive breast cancer
Source: University of Miami Miller School of Medicine From: sciencedaily.com New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that women who live near federally designated Superfund sites face a higher risk of developing aggressive forms of breast cancer — including triple-negative breast cancer, which is especially difficult to treat. Previous research …
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
By: Paige Britt From: targetedonc.com Key Takeaways The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% compared to the standard regimen. Median progression-free survival was 40.7 months, with an overall response rate of 85.1% for T-DXd plus pertuzumab. The safety profile of …
What to Know About Metastatic Breast Cancer in Your 50s
From: healthline.com Although the average age of diagnosis for breast cancer in the United States is 62 yearsTrusted Source, the condition can also affect people in their 50s or at a younger age. Metastatic breast cancer (MBC) occurs when breast cancer spreads from your breast to other parts of your body. There’s currently no cure for MBC, but treatment may …
How Pharmacists Help Drive Precision Oncology in Metastatic Breast Cancer
By: Danielle Valletti, Assistant Editor, Siddhartha Yadav, M.B.B.S., M.D. From: .pharmacytimes.com Pharmacists play a vital role in precision oncology, enhancing treatment decisions for metastatic breast cancer through genetic testing and targeted therapies. At the 2025 San Antonio Breast Cancer Symposium (SABCS), Siddhartha Yadav, MBBS, MD, discussed the critical and expanding role of pharmacists in precision oncology and biomarker-driven treatment decision-making …